These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38103202)

  • 41. Does the COVID-19 XBB Omicron subvariant signal the beginning of the end of the pandemic?
    Ngiam JN; Al-Mubaarak A; Maurer-Stroh S; Tambyah PA
    Singapore Med J; 2022 Dec; ():. PubMed ID: 36648003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2.
    Chiang HL; Liang KH; Lu RM; Kuo TW; Lin YL; Wu HC
    J Biomed Sci; 2023 Jul; 30(1):59. PubMed ID: 37525188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
    Chiba S; Halfmann PJ; Iida S; Hirata Y; Sato Y; Kuroda M; Armbrust T; Spyra S; Suzuki T; Kawaoka Y
    Vaccine; 2023 Sep; 41(41):6025-6035. PubMed ID: 37635002
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
    Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
    J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster.
    Wang X; Jiang S; Ma W; Li X; Wei K; Xie F; Zhao C; Zhao X; Wang S; Li C; Qiao R; Cui Y; Chen Y; Li J; Cai G; Liu C; Yu J; Li J; Hu Z; Zhang W; Jiang S; Li M; Zhang Y; Wang P
    Cell Host Microbe; 2024 Jan; 32(1):25-34.e5. PubMed ID: 38029742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SARS-CoV-2 Omicron XBB lineage spike structures, conformations, antigenicity, and receptor recognition.
    Zhang QE; Lindenberger J; Parsons R; Thakur B; Parks R; Park CS; Huang X; Sammour S; Janowska K; Spence TN; Edwards RJ; Martin M; Williams WB; Gobeil S; Montefiori DC; Korber B; Saunders KO; Haynes BF; Haynes BF; Henderson R; Acharya P
    bioRxiv; 2024 Mar; ():. PubMed ID: 38405707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phenotyping the virulence of SARS-CoV-2 variants in hamsters by digital pathology and machine learning.
    Meehan GR; Herder V; Allan J; Huang X; Kerr K; Mendonca DC; Ilia G; Wright DW; Nomikou K; Gu Q; Molina Arias S; Hansmann F; Hardas A; Attipa C; De Lorenzo G; Cowton V; Upfold N; Palmalux N; Brown JC; Barclay WS; Filipe ADS; Furnon W; Patel AH; Palmarini M
    PLoS Pathog; 2023 Nov; 19(11):e1011589. PubMed ID: 37934791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters.
    Su W; Choy KT; Gu H; Sia SF; Cheng KM; Nizami SIN; Krishnan P; Ng YM; Chang LDJ; Liu Y; Cheng SMS; Peiris M; Poon LLM; Nicholls JM; Yen HL
    J Infect Dis; 2023 May; 227(10):1143-1152. PubMed ID: 35776136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2.
    Thimmiraju SR; Adhikari R; Villar MJ; Lee J; Liu Z; Kundu R; Chen YL; Sharma S; Ghei K; Keegan B; Versteeg L; Gillespie PM; Ciciriello A; Islam NY; Poveda C; Uzcategui N; Chen WH; Kimata JT; Zhan B; Strych U; Bottazzi ME; Hotez PJ; Pollet J
    Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896960
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
    Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
    Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
    J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
    Kurhade C; Zou J; Xia H; Liu M; Chang HC; Ren P; Xie X; Shi PY
    Nat Med; 2023 Feb; 29(2):344-347. PubMed ID: 36473500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant.
    Tsujino S; Deguchi S; Nomai T; Padilla-Blanco M; Plianchaisuk A; Wang L; Begum MM; Uriu K; Mizuma K; Nao N; Kojima I; Tsubo T; Li J; Matsumura Y; Nagao M; Oda Y; Tsuda M; Anraku Y; Kita S; Yajima H; Sasaki-Tabata K; Guo Z; Hinay AA; Yoshimatsu K; Yamamoto Y; Nagamoto T; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Nasser H; Jonathan M; Putri O; Kim Y; Chen L; Suzuki R; Tamura T; Maenaka K; Irie T; Matsuno K; Tanaka S; Ito J; Ikeda T; Takayama K; Zahradnik J; Hashiguchi T; Fukuhara T; Sato K;
    Microbiol Immunol; 2024 Jul; ():. PubMed ID: 38961765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022.
    Vikse EL; Fossum E; Erdal MS; Hungnes O; Bragstad K
    Influenza Other Respir Viruses; 2023 Jun; 17(6):e13144. PubMed ID: 37273461
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population.
    Sutandhio S; Furukawa K; Kurahashi Y; Marini MI; Effendi GB; Hasegawa N; Ishimaru H; Nishimura M; Arii J; Mori Y
    J Infect Public Health; 2023 Jul; 16(7):1064-1072. PubMed ID: 37196370
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genomic Surveillance Reveals the Rapid Expansion of the XBB Lineage among Circulating SARS-CoV-2 Omicron Lineages in Southeastern Wisconsin, USA.
    Ramaiah A; Khubbar M; Akinyemi K; Bauer A; Carranza F; Weiner J; Bhattacharyya S; Payne D; Balakrishnan N
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766346
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
    Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5.
    Tamura T; Yamasoba D; Oda Y; Ito J; Kamasaki T; Nao N; Hashimoto R; Fujioka Y; Suzuki R; Wang L; Ito H; Kashima Y; Kimura I; Kishimoto M; Tsuda M; Sawa H; Yoshimatsu K; Yamamoto Y; Nagamoto T; Kanamune J; Suzuki Y; Ohba Y; ; Yokota I; Matsuno K; Takayama K; Tanaka S; Sato K; Fukuhara T
    Commun Biol; 2023 Jul; 6(1):772. PubMed ID: 37488344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.